This site is intended for healthcare professionals

Longer therapy with puberty delaying medication lowers bone density: Study

Time : 23rd of June 2022 02:15:34 PM Physician/Medicine,Pharma News,Orthopaedics,Endocrinology & Diabetes

The median overall bone density Z-scores were less than 0 for the young transgenders who were using gonadotropin-releasing hormone or estradiol. The bone density Z-score less than 0 suggests a lower bone density in these people than in others of the same age and sex. Also, prolonged therapy with gonadotropin-releasing hormone was linked to a low bone mineral density Z-score.
  The Endocrine Society


Primary hyperparathyroidism could increase the risk of fractures and CVD

Time : 21st of June 2022 09:37:56 AM Orthopaedics,Endocrinology & Diabetes,Cardiology

Patients with primary hyperparathyroidism had a 51%, 45%, and 72% increased risk of hip fractures, cardiovascular events like a heart attack or stroke, and death, respectively, according to a study. However, patients with primary hyperparathyroidism who underwent partial or entire parathyroidectomy experienced a reduced risk of fractures and CVD.
  University of Gothenburg


Pain can be common after surgery of hip fracture regardless of anaesthesia type

Time : 17th of June 2022 10:26:58 AM Orthopaedics,Anesthesia

Over 73% of the patients who received spinal or general anaesthesia reported severe pain during the initial 24 hours following the surgery, as per the REGAIN trial. Compared to patients on general anaesthesia, patients who received spinal anaesthesia reported worse pain in the first 24 hours following surgery, and more of them used prescription analgesics till 60 days.
  Docsvalley


A new treatment could be a preferred treatment for classical Hodgkin lymphoma

Time : 15th of June 2022 10:59:56 AM Orthopaedics

At a median follow-up of 73 months, 39 overall survival events occurred in the brentuximab vedotin, doxorubicin, vinblastine and dacarbazine (A+AVD) arm than 64 in the doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD), as per a study. These findings favoured A+AVD. Also, 6-year progression-free survival was 82.3% with A+AVD and 74.5% with ABVD.
  


A new injectable hydrogel reduces the chronic lower back pain

Time : 13th of June 2022 09:14:41 AM Physician/Medicine,Pharma News,Orthopaedics

The new experimental hydrogel was safe and effective when injected into spinal discs for relieving chronic lower back pain in patients with degenerative disc disease, as per a study. The self-reported back pain score reduced from 7.1 to 2 after six months of hydrogel treatment. Also, injectable hydrogel improved the physical functioning of the patients with back pain.
  Study Finds


FDA grants RIABNI with a new indication for treating rheumatoid arthritis

Time : 9th of June 2022 01:51:50 PM Physician/Medicine,Pharma News,Orthopaedics

Amgen announced that the US FDA approved RIABNI (rituximab-arrx), a biosimilar medication to Rituxan (rituximab), in combination with methotrexate to treat adults with moderate and severely active rheumatoid arthritis who showed an inadequate response to TNF antagonist therapies. RIABNI is a CD20-directed cytolytic antibody with similar safety and efficacy to Rituxan's.


  Amgen


Reactive arthritis in a young adult without known medical history

Time : 8th of June 2022 02:55:53 PM Physician/Medicine,Orthopaedics,Nursing

A 40-year-old man presented to a clinic with a 2-week history of joint swelling, scaly foot rash and lower back pain. The patient's clinical and lab findings were consistent with non-infectious inflammatory arthritis. Testing for HLA-B27 was positive. He was diagnosed with reactive arthritis and was treated with NSAIDs, sulfasalazine, and systemic glucocorticoids.


  Twitter @NEJM


ASAS/EULAR committee issues guidance on the management of patients with axSpA

Time : 8th of June 2022 02:44:40 PM Physician/Medicine,Orthopaedics

The new recommendation stated that recurrent uveitis monoclonal antibody should be preferred against TNF-alpha in patients with a history of active inflammatory bowel disease, while IL-17 inhibitors must be given to patients with psoriasis. Also, patients' diagnoses should be reevaluated, and their comorbidities must be considered if they do not respond to current treatment.


  Docsvalley


At-home employees are at an increased risk of developing lower back pain

Time : 6th of June 2022 03:29:46 PM Physician/Medicine,Orthopaedics

Employees who worked from home sat for nearly 1 hour per day more compared to those who returned to the office, as per a study. Also, these people had a higher risk for lower back pain due to extended time spent sitting and poor ergonomics. Additionally, increased sitting time can be associated with excessive hip flexion and postural deviation at the knee.


  Docsvalley


SGLT2 inhibitors could not increase the risk of fracture

Time : 6th of June 2022 01:53:59 PM Pharma News,Orthopaedics,Endocrinology & Diabetes

Initiating therapy with a sodium-glucose cotransporter-2 (SGLT2) inhibitor versus a dipeptidyl peptidase-4 inhibitor in patients with diabetes was not associated with an increased risk of skeletal fractures, according to a study. No fracture risk was observed even in patients with CKD with an estimated glomerular filtration rate of 30–90 ml/minute per 1.73 m2.


  Twitter @CJASN